360Dx — Proteomics International Laboratories Transfers Diabetic Kidney Disease Test Tech to Atturos
“NEW YORK — Proteomics International Laboratories said on Thursday that it has completed the...
“Proteomics International Laboratories Ltd, a medical technology company headquartered in Perth, Australia, has announced the successful transfer of its PromarkerD technology to the laboratories of clinical diagnostics partner, Atturos, a spin-out of University College Dublin…
Proteomics has also announced the launch of PromarkerD in the first European country, Spain following the completion of a licensing deal with Patia Europe. Patia Europe is commercialising PromarkerD with the Laboratory Developed Test (LDT) being offered by Atturos…
In the clinical study PromarkerD correctly predicted 86 per cent of otherwise healthy diabetic patients who went on to develop chronic kidney disease within four years.”
Article: Test to predict onset of diabetic kidney disease step closer to launch across Europe
Test to predict onset of diabetic kidney disease step closer to launch across Europe
“NEW YORK — Proteomics International Laboratories said on Thursday that it has completed the...
PromarkerD was showcased at the 55th Annual Meeting of the European Association for the Study of...
“Proteomics International Laboratories has secured CE Mark registration for its PromarkerD as a...